SCHEMBL7175193

SCHEMBL7175193

COc1cc(OC)c(C(=O)P(=O)(C(=O)c2c(C(C)(C)C)cc(C(C)(C)C)cc2C(C)(C)C)c2ccccc2)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.40
MAPT P10636 5/20 0.38
TP53 P04637 3/20 0.38
KMT2A Q03164 3/20 0.38
CYP3A4 P08684 2/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NR1H4 Q96RI1 4/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
MAPK1 P28482 2/20 0.35
USP2 O75604 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
LMNA P02545 1/20 0.34
STAT1 P42224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185487 0.91 CA12 (0.41) MAPTTP53KMT2ANR1H4NPSR1
SCHEMBL7178020 0.89 KMT2A (0.39) LPAR1MAPTTP53KMT2ACYP3A4
SCHEMBL2768729 0.86 KMT2A (0.47) MAPTTP53KMT2ACYP3A4ATM
SCHEMBL7177661 0.83 FABP4 (0.37) MAPTNR1H4NPSR1RAB9ASMN1; SMN2
SCHEMBL7188964 0.82 MAPT (0.48) MAPTTP53KMT2ACYP3A4ATM
SCHEMBL7178308 0.82 KMT2A (0.42) MAPTTP53KMT2ACYP3A4ATM
SCHEMBL7183900 0.81 MEN1 (0.39) MAPTTP53KMT2ACYP3A4NR1H4
SCHEMBL7175523 0.81 KMT2A (0.43) MAPTTP53KMT2ACYP3A4ATM
SCHEMBL7190322 0.81 NR1H4 (0.37) MAPTTP53KMT2ANR1H4NPSR1
SCHEMBL7181280 0.80 KMT2A (0.42) MAPTTP53KMT2ACYP3A4ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LPAR1 499/4885MAPT 4870/4885TP53 3575/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LPAR1 536/4885MAPT 4859/4885TP53 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.